FDA proposes guidance on using overall survival endpoints in cancer drug trials
Regulatory NewsFerdous Al-Faruque
GuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsFerdous Al-FaruqueGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)